Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

Polman CH(2006)A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899-910

O’Connor PW(2009)Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis (AFFIRM) study Lancet Neurol 8 254-260

Havrdova E(2014)Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results J Neurol Neurosurg Psychiatry 85 1190-1197

Havrdova E(2020)Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP) J Neurol Neurosurg Psychiatry 91 660-668

Galetta S(2011)Natalizumab for relapsing remitting multiple sclerosis Cochrane Database Syst Rev 10 CD007621-812

Hutchinson M(2014)Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy Ann Neurol 76 802-87

Butzkueven H(2019)Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab Mult Scler Relat Disord 33 82-2443

Kappos L(2017)Towards personalized therapy for multiple sclerosis: prediction of individual treatment response Brain 140 2426-147

Pellegrini F(2016)Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis J Neurol Sci 15 145-19

Butzkueven H(2018)Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting Mult Scler Relat Disord 24 11-56

Polman CH(2006)A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899-910

O’Connor PW(2009)Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis (AFFIRM) study Lancet Neurol 8 254-260

Havrdova E(2014)Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results J Neurol Neurosurg Psychiatry 85 1190-1197

Havrdova E(2020)Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP) J Neurol Neurosurg Psychiatry 91 660-668

Galetta S(2011)Natalizumab for relapsing remitting multiple sclerosis Cochrane Database Syst Rev 10 CD007621-812

Hutchinson M(2014)Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy Ann Neurol 76 802-87

Butzkueven H(2019)Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab Mult Scler Relat Disord 33 82-2443

Kappos L(2017)Towards personalized therapy for multiple sclerosis: prediction of individual treatment response Brain 140 2426-147

Pellegrini F(2016)Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis J Neurol Sci 15 145-19

Butzkueven H(2018)Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting Mult Scler Relat Disord 24 11-56